Evidence map›Paper›PMID 35927542›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2023

Assessment of health-related quality of life in Australian patients with idiopathic pulmonary fibrosis: a comparison of the EQ-5D-5L and the AQoL-8D.

Ingrid A Cox, Julie Campbell, Barbara de Graaff, Petr Otahal, Tamera J Corte, Yuben Moodley, Peter Hopkins, Sacha Macansh, E Haydn Walters, Andrew J Palmer

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Ingrid A CoxMenzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia.ORCID http://orcid.org/0000-0001-5130-4088
Julie CampbellMenzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia.
Barbara de GraaffMenzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia.
Petr OtahalMenzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia.
Tamera J CorteNHMRC Centre of Research Excellence for Pulmonary Fibrosis, Melbourne, Australia.
Yuben MoodleyNHMRC Centre of Research Excellence for Pulmonary Fibrosis, Melbourne, Australia.
Peter HopkinsNHMRC Centre of Research Excellence for Pulmonary Fibrosis, Melbourne, Australia.
Sacha MacanshAustralian Idiopathic Pulmonary Fibrosis Registry, Lung Foundation of Australia, New South Wales, Australia.
E Haydn WaltersMenzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia.
Andrew J PalmerMenzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia. andrew.palmer@utas.edu.au.
University of Tasmania · AULung Foundation Australia · AUThe University of Queensland · AUThe University of Sydney · AUThe University of Western Australia · AU

Funding

Boehringer Ingelheim Not ApplicableGalapagos Conservancy Not ApplicableNational Health and Medical Research Council GNT1116371Roche Not Applicable
6 · The paper itself

Abstract

purposeIdiopathic pulmonary fibrosis (IPF) is a progressive and debilitating chronic lung disease with a high symptom burden, which has a substantial impact on health-related quality of life (HRQoL). Our study aimed to assess the suitability of the EuroQol five-dimension (EQ-5D-5L) and the Assessment of Quality of Life- eight-dimension (AQoL-8D) questionnaires in measuring HRQoL as health state utility values (HSUVs) in an Australian IPF cohort.

methodsData for estimation of health state utility values (HSUVs) were collected from participants of the Australian IPF Registry (AIPFR) using self-administered surveys which included the EQ-5D-5L and the AQoL-8D. Data on lung function and disease specific HRQoL instruments were collected from the AIPFR. Performance of the two instruments was evaluated based on questionnaire practicality, agreement between the two instruments and test performance (internal and construct validity).

resultsOverall completion rates for the EQ-5D-5L and AQoL-8D were 96% and 85%, respectively. Mean (median) HSUVs were 0.65 (0.70) and 0.69 (0.72) for the EQ-5D-5L and AQoL-8D, respectively. There was reasonable agreement between the two instruments based on the Bland-Altman plot mean difference (-0.04) and intraclass correlation coefficient (0.84), however there were some fundamental differences. A larger range of values was observed with the EQ-5D-5L (-0.57-1.00 vs 0.16-1.00). The EQ-5D-5L had a greater divergent sensitivity and efficacy in relation to assessing HSUVs between clinical groupings. The AQoL-8D ,however, had a higher sensitivity to measure psychosocial aspects of HRQoL in IPF.

conclusionThe EQ-5D-5L demonstrated superior performance when compared to AQoL-8D in persons with IPF. This may be attributable to the high symptom burden which is physically debilitating to which the EQ-5D-5L may be more sensitive.

Indexed as

Quality of LifeAustraliaHumansPsychometricsSurveys and QuestionnairesAQoL-8DEQ-5D-5LHealth-related quality of lifeIdiopathic pulmonary fibrosisUtility values

Identifiers

PMID35927542
PMCPMC9911478
OpenAlexW4289834806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.